Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nektar Therapeutics (GB:0UNL)
LSE:0UNL
Nektar Therapeutics (0UNL) Share Price & Analysis
0 Followers
0UNL Stock Chart & Stats
Day’s Range$1.32 - $1.37
52-Week Range― - ―
Previous Close$1.4
Volume2.02K
Average Volume (3M)N/A
Market Cap
$260.74M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 08, 2024EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1.00Price Target Upside-24.24% Downside
Rating ConsensusHold
Number of Analyst Covering1
Nektar Therapeutics News
PremiumCompany Announcements
Nektar Therapeutics Is Worried About This – Should You Be Worried Too?
Options Prices
Currently, No data available
---
Ownership Overview
2.34% Insiders
20.01% Mutual Funds
6.86% Other Institutional Investors
70.79% Public Companies and
Individual Investors
0UNL FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Nektar Therapeutics’s market cap?
Currently, no data Available
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is May 08, 2024 which is in 11 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on Mar 04, 2024. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.21 by -$0.01.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Overvalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -$0.19.
How many shares outstanding does Nektar Therapeutics have?
Currently, no data Available
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.21. Following the earnings report the stock price went down -6.519%.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Among the largest hedge funds holding Nektar Therapeutics’s share is PRIMECAP Management Co. It holds Nektar Therapeutics’s shares valued at 4M.
---
Nektar Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (-24.24% Downside)
$1.00 (-24.24% Downside)
Blogger Sentiment
Bullish
GB:0UNL Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $19.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.10%
12-Months-Change
Fundamentals
Return on Equity
-110.95%
Trailing 12-Months
Asset Growth
-43.99%
Trailing 12-Months
Company Description
Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
---
0UNL Earnings Call
Q4 2024
0:00 / 0:00
---
0UNL Stock 12 Months Forecast
Average Price Target
$1.00
▼(-24.24% Downside)
Technical Analysis
Best Analysts Covering 0UNL
1 Year
1 Year Success Rate
10/15 ratings generated profit
1 Year Average Return
+50.37%
initiated a sell rating 5 months ago
Copying Jessica Fye's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +50.37% per trade.
---